Mindfulness-based cognitive therapy linked to large reductions in distress and fatigue in cancer patients

The study found large, statistically significant reductions in psychological distress (standardized mean difference [SMD] = −0.81), depression (SMD = −0.95), and anxiety (SMD = −0.86), with 95% confidence intervals not crossing zero. Secondary outcomes showed MBCT was also associated with marked decreases in fatigue (SMD = −0.83), improvements in quality of life (SMD = 0.56), and enhanced mindfulness skills (SMD = 0.76). This meta-analysis represents the first systematic synthesis of RCT evidence for standardized MBCT specifically in cancer care, suggesting dual emotional and physical benefits. A key limitation is the predominantly female sample (91%), which may limit generalizability to male cancer patients and other demographic groups.

The effect sizes here are notably large across all three primary psychological measures—depression's SMD of −0.95 and anxiety's −0.86 exceed typical pharmacological benchmarks in oncology psychology. Fatigue reduction (SMD = −0.83) is clinically meaningful because cancer-related fatigue is notoriously resistant to treatment and significantly impairs daily functioning; this represents one of the few non-pharmacological interventions showing such a robust effect on this outcome. The quality-of-life improvement (SMD = 0.56) was moderate but consistent across trials, and the enhancement in mindfulness skills (SMD = 0.76) suggests MBCT was delivered with fidelity and participants engaged meaningfully. The sample skew toward women (91%) and inclusion of all cancer types and stages mean results may not extrapolate equally to men with cancer or to early versus late-stage disease—future trials should stratify by sex and stage. Heterogeneity in control conditions (some passive, some active) and variation in MBCT dosage (8-week to longer formats) may also explain some scatter in effect estimates.